Facility will manufacture new and existing products including hemophilia drug, growth hormone, and glucagon product.


Novo Nordisk will invest about DKK 1 billion (roughly €134 million, or $192 million) in the construction of a new facility in Denmark for the production of biopharmaceuticals.

The new facility, for which the plans have just been approved, will include formulation, freeze-drying, filling, and packaging of a number of Novo Nordisk’s existing and future biopharmaceuticals, including its NovoSeven® hemophilia drug, Norditropin growth hormone and GlucaGen glucagon products.

The firm says the packaging facility at the new plant is expected to be operational in 2013, with the remaining facilities coming on stream in 2015 after approval. Novo Nordisk already operates a biopharmaceutical production plant in Denmark.








This site uses Akismet to reduce spam. Learn how your comment data is processed.